Travere Therapeutics, Inc.
NASDAQTravere Therapeutics delivered its Q2 earnings on August 4 and the Street's response was immediate — multiple firms lifted targets on the same morning, validating the bullish setup that had been building for weeks. The analyst reaction was unusually coordinated. Citigroup raised its target from $70 to $85, Guggenheim moved from $65 to $75, and Evercore ISI lifted from $60 to $68…
Snapshot as of 19 Aug 2026
Travere Therapeutics delivered its Q2 earnings on August 4 and the Street's response was immediate — multiple firms lifted targets on the same morning, validating the bullish setup that had been building for weeks. The…
TVTX heads into its August 6 earnings print with short sellers retreating and analysts raising targets — a rare alignment of two signals pointing in the same direction. Short interest has declined meaningfully over the…
Travere Therapeutics heads into early June with a familiar tension: analysts raising targets and the Street broadly bullish on FILSPARI's rare-disease story, while a 15.6% short interest and a cluster of insider…
Travere Therapeutics arrives at the close of this week carrying two competing stories: a Q1 earnings beat that pulled the entire sell-side to raise its targets, and a cluster of insider sales from the same management…
Travere Therapeutics heads into its May 7 earnings with a striking divergence: short sellers have been exiting while analysts race to raise targets, leaving the stock 47% higher than a month ago with defensive options…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TVTX — free to start on ORTEX.
Sign up for free →Open TVTX on ORTEX